# EDGAR Filing Document

**Accession Number:** 0001348362
**File Stem:** 0001640334-26-000162
**Filing Date:** 2026-1
**Character Count:** 5862
**Document Hash:** e837629160e835cc33a3b30501874de4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640334-26-000162.hdr.sgml**: 20260128

**ACCESSION NUMBER**: 0001640334-26-000162

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260127

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260128

**DATE AS OF CHANGE**: 20260128

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lexaria Bioscience Corp.
- **CENTRAL INDEX KEY:** 0001348362
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 202000871
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39874
- **FILM NUMBER:** 26571414

**BUSINESS ADDRESS:**
- **STREET 1:** 100 - 740 MCCURDY ROAD
- **CITY:** KELOWNA
- **STATE:** A1
- **ZIP:** V1X 2P7
- **BUSINESS PHONE:** 250-765-6424

**MAIL ADDRESS:**
- **STREET 1:** 100 - 740 MCCURDY ROAD
- **CITY:** KELOWNA
- **STATE:** A1
- **ZIP:** V1X 2P7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEXARIA CORP.
- **DATE OF NAME CHANGE:** 20080229

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lexaria Corp.
- **DATE OF NAME CHANGE:** 20051229

?xml version='1.0' encoding='ASCII'? lxrp_8k.htm

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) **<u>January 27, 2026</u>**

---

| |
|:---|
| **LEXARIA BIOSCIENCE CORP.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **000-39874** | **20-2000871** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **100 – 740 McCurdy Road, Kelowna, BC Canada**  | **V1X 2P7** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code **<u>(250) 765-6424</u>**

(Former name or former address, if changed since last report.)<br>

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐&nbsp;&nbsp;&nbsp;&nbsp; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | LEXX | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

**Item 5.07 Submission of Matters to a Vote of Security Holders**

On January 27, 2026 at 1:00 p.m. (Pacific Time), the Company held its annual shareholder meeting (the "Meeting"). There were 8,380,389 shares of the Company represented in person or by proxy at the Meeting, constituting 37.71% of the Company's issued share capital as at December 1, 2025, being the record date of the Meeting. The matters voted upon at the Meeting and the final voting results are set forth below:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Matter Being Voted On** | **For** | **Against/**<br>**Withheld** | **Abstain**  | **Broker Non-Vote** | **Percent**<br>**Approved By<sup>1</sup>** |
| To Elect Richard Christopher as a director | 3610713 | 806470 | - | 3963206 | 81.7% |
| To Elect John Docherty as a director | 4258174 | 159008 | - | 3963207 | 96.4% |
| To Elect Christopher Bunka as a director | 3779780 | 637402 | - | 3963207 | 85.6% |
| To Elect Nicholas Baxter as a director | 4082174 | 335009 | - | 3963206 | 92.4% |
| To Elect William Edward (Ted) McKechnie as a director | 3645373 | 771809 | - | 3963207 | 82.5% |
| To Elect Albert Reese Jr. as a director | 3252873 | 1164310 | - | 3963206 | 73.6% |
| To Elect Bal Bhullar as a director | 4119098 | 298085 | - | 3963206 | 93.3% |
| To Appoint Malone Bailey LLP as Auditors | 8070899 | 252955 | 56535 | - | 97.0% |
| To Ratify the lawful actions of the directors for the past year | 3913888 | 437312 | 65982 | 3963207 | 90.0% |

---

<sup>1</sup> Percentage is calculated based on abstained votes and broker non-votes not being counted as a vote against the resolution.

All of the proposals are described in detail in the Company's proxy statement filed with the Securities and Exchange Commission on December 10, 2025.

2<br>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| |
|:---|
| **LEXARIA BIOSCIENCE CORP.** |
| */s/ Richard Christopher* |
| **Richard Christopher** |
| CEO, Principal Executive Officer |
| Date: January 28, 2026 |

---

3<br>